-
Maresca defends Donnarumma, Guehi after Man City defeat
-
Greenhouse gas levels hit new record highs in 2025: UN
-
Nordic leaders call Putin as local truce begins in Ukraine
-
Rybakina looking to clinch year-end number one in Tokyo
-
Osaka unveils crane outfit in Tokyo before win over Paolini
-
Tech firms track Wall St rally on mixed day for stock markets
-
Ronaldo in line for Portugal return after fallout with coach
-
Kane says Ballon d'Or win 'feels like a dream' as tributes pour in
-
Norway media take legal action to block Meta from using content
-
HSBC profit jumps on higher rates, lower costs
-
Bayern praise 'humble' Kane after Ballon d'Or win
-
Rams rediscover offensive balance in 35-21 victory over Raiders
-
Colts retain Daniel Jones as starter despite continued offensive struggles
-
Mercedes-Benz cuts 2026 profit outlook on tough China market
-
Madushanka wrecks Pakistan as Sri Lanka press for final slot
-
Reparations calls follow Charles on tough Caribbean trip
-
Destructive Abhishek 113 leads India to series win over New Zealand
-
Jammu and Kashmir ministers resign before planned council expansion
-
Norway, Finland leaders hold 'frank and substantive' talk with Putin
-
Germany, EU, stable investment stops despite upheaval: Merz
-
Wall Street faces earnings and Fed tests after turbulent technology-led week
-
China brands drop Mbappe for 'offending national sentiments'
-
Ukraine, Russia say US-brokered truce holding in ravaged city
-
India orders evacuations as Cyclone Arnab looms
-
Police form SIT after vehicles in Rahul Gandhi convoy collide on expressway
-
Dutch broadcaster pulls out of Eurovision over Israel 'sensitivities'
-
Delhi grants minimum monthly pay and DA to about 4,000 MCD health workers
-
Critical coal inventories affect nearly half of India’s domestic power plants
-
Ather Energy shares climb 14% after quarterly profit and expansion plan
-
FCNR(B) deposit drive puts sharper margin pressure on private banks
-
Gold ETF flows turn negative after 13 weeks as bullion loses 4%
-
Noel Tata requests records of September 17 Tata Sons board meeting
-
Pakistan's last antique restorers give old treasures new life
-
Reparations calls to dog King Charles's tough Caribbean trip
-
India braces for Cyclone Arnab with evacuations
-
Global rates and foreign outflows remain key risks for Indian markets
-
Steel Strips Wheels gains 36% in two sessions on growth outlook
-
Neha Nagar says ₹3 crore can fund retirement with disciplined planning
-
Cavs edge T'Wolves in overtime despite superb Edwards
-
Vikas Satija says steady SIP flows shielded Indian equities from deeper losses
-
Prescott fires Cowboys to 38-21 win over plummeting Eagles
-
Brewers rout Rays to reach brink of World Series sweep
-
Kuwait padel chief hails national showing at Premier Padel Major
-
Mbappe dropped by Chinese brands for 'offending national sentiments'
-
Britain prepares constrained budget as debt and defence pressures mount
-
Kuwait exhibition presents Ukraine’s Islamic heritage and cultural ties
-
Valkyries beat Dream to reach brink of WNBA title
-
Tech firms track Wall St rally on mixed day for Asian markets
-
Benjamin Netanyahu: Israel's longest-serving PM fighting for survival
-
Jay-Z to perform at Super Bowl LXI halftime show: NFL
Treatment improves cognition in Down Syndrome patients
A new hormone treatment improved the cognitive function of six men with Down Syndrome by 10-30 percent, scientists said Thursday, adding the "promising" results may raise hopes of improving patients' quality of life.
However the scientists emphasised the small study did not point towards a cure for the cognitive disorders of people with Down Syndrome and that far more research is needed.
"The experiment is very satisfactory, even if we remain cautious," said Nelly Pitteloud of Switzerland's Lausanne University Hospital and co-author of a new study in the journal Science.
Down Syndrome is the most common genetic form of intellectual disability, occurring in around one in 1,000 people, according to the World Health Organization.
Yet previous research has failed to significantly improve cognition when applied to people with the condition, which is why the latest findings are "particularly important", the study said.
Recent discoveries have suggested that how the gonadotropin-releasing hormone (GnRH) is produced in the brain can affect cognitive functioning such as memory, language and learning.
GnRH hormones regulate how much testosterone and estrogen is produced and increased levels of it help spur puberty.
"We wondered if this hormone could play any role in establishing the symptoms of people with Down Syndrome," said Vincent Prevot, study co-author and head of neuroscience research at France's INSERM institute.
- Mice research -
The team first established that five strands of microRNA regulating the production of GnRH were dysfunctional in mice specifically engineered for Down Syndrome research.
They then demonstrated that cognitive deficiencies -- as well as loss of smell, a common symptom of Down Syndrome -- were linked to dysfunctioning GnRH secretion in the mice.
The team then gave the mice a GnRH medication used to treat low testosterone and delayed puberty in humans, finding that it restored some cognitive function and sense of smell.
A pilot study was conducted in Switzerland involving seven men with Down Syndrome aged 20 to 50.
They each received the treatment through their arm every two hours over a period of six months, with the drug delivered in pulses to mimic the hormone's frequency in people without Down Syndrome.
Cognition and smell tests were carried out during the treatment, as were MRI scans.
Six of the seven men showed improvement in cognition with no significant side effects -- however none showed a change in their sense of smell.
"We have seen an improvement of between 10-30 percent in cognitive functions, in particular with visuospatial function, three-dimensional representation, understanding of instructions as well as attention," Pitteloud said.
The patients were asked to draw a simple 3D bed at several stages throughout the therapy. Many struggled at the beginning but by the end the efforts were noticeably better.
- 'Improve quality of life' -
The authors acknowledged some limitations of the study, including its size and that the choice of patients was "pushed by their parents".
"The clinical trial only focused on seven male patients -- we still have a lot of work to do to prove the effectiveness of GnRH treatment for Down Syndrome," Pitteloud said.
A larger study involving a placebo and 50 to 60 patients, a third of them women, is expected to begin in the coming months.
"We are not going to cure the cognitive disorders of people with Down Syndrome, but the improvement seen in our results already seems fundamental enough to hope to improve their quality of life," Pitteloud said.
Fabian Fernandez, an expert in cognition and Down Syndrome at the University of Arizona who was not involved in the research, hailed the "tour de force study".
He told AFP that while it is "difficult to envision" how such an intensive treatment could be used for young people, it might be better suited to delay the Alzheimer's disease-related dementia suffered by many adults with Down Syndrome.
It was also difficult to predict how such an improvement could impact the lives of people with the condition, he said.
"For some, it could be significant, however, as it would enable them to be more independent with daily living activities such as maintaining and enjoying hobbies, finding belongings, using appliances in the home, and travelling alone."
M.AbuKhalil--SF-PST